Literature DB >> 15634031

The influence of age and sex on the clearance of cytochrome P450 3A substrates.

Monette M Cotreau1, Lisa L von Moltke, David J Greenblatt.   

Abstract

Cytochrome P450s (CYPs) are an important family of enzymes in the metabolism of many therapeutic agents and endogenous metabolic reactions. The CYP3A subfamily is especially prominent in these metabolic activities. This review article focuses on how the factors of age and sex may influence the in vivo activity of human CYP3A. The functional activity of CYP3A varies based on issues such as interaction with one or more substrates and between individuals and/or localisation. For CYP3A substrates, intrinsic clearance is the component of total clearance that is contributed by the enzymes. Depending on the route of administration and the contribution of hepatic blood flow to overall clearance, sensitivities to changes in CYP3A activities may differ. Additionally, age may influence the hepatic blood flow and, in turn, affect CYP3A activity. A review of the literature regarding age influences on the clearance of CYP3A substrates does suggest that age can affect the clearance of certain CYP3A substrates.CYP3A is responsible for a large number of endogenous metabolic reactions involving steroid hormones, and enzyme activity has been reported to be induced and/or inhibited in the presence of some sex steroids. Based on published studies for most CYP3A substrates, sex does not appear to influence clearance; however, with certain substrates significant sex-related differences are found. In such cases, women primarily have higher clearance than men.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15634031     DOI: 10.2165/00003088-200544010-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  200 in total

1.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

Authors:  T Kronbach; D Mathys; M Umeno; F J Gonzalez; U A Meyer
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

2.  Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes.

Authors:  L C Wienkers; R C Steenwyk; P E Sanders; P G Pearson
Journal:  J Pharmacol Exp Ther       Date:  1996-05       Impact factor: 4.030

3.  The genetic determinants of the CYP3A5 polymorphism.

Authors:  E Hustert; M Haberl; O Burk; R Wolbold; Y Q He; K Klein; A C Nuessler; P Neuhaus; J Klattig; R Eiselt; I Koch; A Zibat; J Brockmöller; J R Halpert; U M Zanger; L Wojnowski
Journal:  Pharmacogenetics       Date:  2001-12

4.  Cocaine pharmacokinetics in men and in women during the follicular and luteal phases of the menstrual cycle.

Authors:  J H Mendelson; N K Mello; M B Sholar; A J Siegel; M J Kaufman; J M Levin; P F Renshaw; B M Cohen
Journal:  Neuropsychopharmacology       Date:  1999-08       Impact factor: 7.853

5.  Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.

Authors:  A D Rodrigues; E M Roberts; D J Mulford; Y Yao; D Ouellet
Journal:  Drug Metab Dispos       Date:  1997-05       Impact factor: 3.922

6.  Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil.

Authors:  M E Krecic-Shepard; C R Barnas; J Slimko; J B Schwartz
Journal:  Clin Pharmacol Ther       Date:  2000-09       Impact factor: 6.875

7.  Pharmacokinetics of buspirone in elderly subjects.

Authors:  R E Gammans; M L Westrick; J P Shea; R F Mayol; J A LaBudde
Journal:  J Clin Pharmacol       Date:  1989-01       Impact factor: 3.126

8.  Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.

Authors:  K S Lown; J C Kolars; K E Thummel; J L Barnett; K L Kunze; S A Wrighton; P B Watkins
Journal:  Drug Metab Dispos       Date:  1994 Nov-Dec       Impact factor: 3.922

9.  Clarithromycin pharmacokinetics in healthy young and elderly volunteers.

Authors:  S Y Chu; D S Wilson; D R Guay; C Craft
Journal:  J Clin Pharmacol       Date:  1992-11       Impact factor: 3.126

10.  Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme.

Authors:  D J Waxman; C Attisano; F P Guengerich; D P Lapenson
Journal:  Arch Biochem Biophys       Date:  1988-06       Impact factor: 4.013

View more
  66 in total

1.  Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.

Authors:  Haiyan Li; Kathleen Butler; Li Yang; Zhenghua Yang; Renli Teng
Journal:  Clin Drug Investig       Date:  2012-02-01       Impact factor: 2.859

Review 2.  Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy.

Authors:  Joseph L Tan; Jacques G Eastment; Arjun Poudel; Ruth E Hubbard
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

3.  Score model for predicting acute-on-chronic liver failure risk in chronic hepatitis B.

Authors:  Fang-Yuan Gao; Yao Liu; Xiao-Shu Li; Xie-Qiong Ye; Le Sun; Ming-Fan Geng; Rui Wang; Hui-Min Liu; Xiao-Bing Zhou; Li-Li Gu; Yan-Min Liu; Gang Wan; Xian-Bo Wang
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

Review 4.  Pharmacogenetics as a tool to tailor antiretroviral therapy: A review.

Authors:  Antonio Aceti; Laura Gianserra; Lara Lambiase; Alfredo Pennica; Elisabetta Teti
Journal:  World J Virol       Date:  2015-08-12

5.  Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years.

Authors:  Vincent Jullien; Saïk Urien; Déborah Hirt; Constance Delaugerre; Elisabeth Rey; Jean-Paul Teglas; Paula Vaz; Christine Rouzioux; Marie-Laure Chaix; Eugenia Macassa; Ghislaine Firtion; Gérard Pons; Stéphane Blanche; Jean-Marc Tréluyer
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 6.  The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships.

Authors:  Pietro Fagiolino; Rosa Eiraldi; Marta Vázquez
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 7.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 8.  Is antiarrhythmic treatment in the elderly different? a review of the specific changes.

Authors:  Vera H M Deneer; Norbert M van Hemel
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 9.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

10.  Effect of hepatic function on the EC50 of midazolam and the BIS50 at the time of loss of consciousness.

Authors:  Yu-hong Li; Rui He; Jin-guang Ruan
Journal:  J Zhejiang Univ Sci B       Date:  2014-08       Impact factor: 3.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.